BIO Comments on Patient-Focused Drug Development Guidance: Methods to Identify What Is Important to Patients and Select, Develop, or Modify Fit-for-Purpose Clinical Outcome Assessments
December 14, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) open docket, Patient-Focused Drug Development Guidance: Methods to Identify What Is Important to Patients and Select, Develop, or Modify Fit-for-Purpose Clinical Outcome Assessments.
BIO commends the FDA for working to ensure patient experiences are more systematically collected and used in the development and review of new therapies. In particular, BIO appreciates the work to develop guidance documents and discussion guides prior to public meetings.
To truly support patient-focused drug development, BIO believes patient experience data should be considered for use throughout the development and review lifecycle. Appropriate “fit-for-purpose” tools for collecting patient experience data have the potential to inform many aspects of drug development and assessment. To encourage stakeholders to collect fit-for-purpose patient experience data, BIO requests FDA publicly and clearly explain how and when they will use patient experience data in different drug development and regulatory decisions. In addition, BIO provides general comments and line edits as well as responses to questions posed by the FDA in the open docket.
Download Full Comments Below
BIO LETTER Patient Focused Drug Development Guidance Methods To Identify What Is Important To Patients FDA–2018-N-2455 0
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
BIO submitted comments on the Food and Drug Administration’s (FDA) open docket, Patient-Focused Drug Development Guidance: Methods to Identify What Is Important to Patients and Select, Develop, or Modify Fit-for-Purpose Clinical Outcome Assessments.
BIO commends the FDA for working to ensure patient experiences are more systematically collected and used in the development and review of new therapies. In particular, BIO appreciates the work to develop guidance documents and discussion guides prior to public meetings.
To truly support patient-focused drug development, BIO believes patient experience data should be considered for use throughout the development and review lifecycle. Appropriate “fit-for-purpose” tools for collecting patient experience data have the potential to inform many aspects of drug development and assessment. To encourage stakeholders to collect fit-for-purpose patient experience data, BIO requests FDA publicly and clearly explain how and when they will use patient experience data in different drug development and regulatory decisions. In addition, BIO provides general comments and line edits as well as responses to questions posed by the FDA in the open docket.